Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease that can adversely affect functional capabilities, if left untreated, leading to irreparable damage to joint spaces [1]. Secukinumab, a biologic agent antagonizing the interleukin-17A (IL-17A) receptor, approved by the Food and Drug Administration (FDA) in 2015, has been indicated for the treatment of moderate to severe plaque psoriasis and active PsA [1]. When compared with the general population, patients with PsA present with decreased quality-of-life and impairment of functional capacity.
